The potential of this approach was highlighted in a case report of a patient with KRAS G12D-mutated PDAC, who had a lung-only metastasis and experienced a partial response (72% tumor regression) following infusion of autologous T cells that were engineered to express HLA-C*08:02–restricted T-cell receptors (TCRs) targeting oncogenic KRAS G12D [59]. The gene discussed is KRAS; the disease is neoplasm.